Consensus Veru Inc.

Stocks

VERU

US92536C2026

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-07 EDT			5-day change	1st Jan Change
2.460 ^USD	-0.40%		-7.52%	+14.95%

09-08	Veru Advances Oral Sabizabulin into Planned Phase 2 Clinical Trial for Daraxonrasib Resistant Metastatic Pancreatic Cancer	CI
08-10	Veru Inc., Q3 2026 Earnings Call, Aug 10, 2026

Evolution of the Average Target: Veru Inc.

Evolution of the Target Price: Veru Inc.

Changes in Analyst Recommendations: Veru Inc.

b7158fde.J45aH2jFLL0L8wcOBPjIwBQb484Fk_P9BH029VyNc24.Rs05cQeab-Jmqz55XdWft35Np4M1x7WXRhl5wWXfRltK7DtPJL1j50O3bA~a5a49fa166818c8bf7ea173e49e05e8b

Analysts' recommendations: Veru Inc.

05-15	Oppenheimer Adjusts Price Target on Veru to $24 From $25, Maintains Outperform Rating	MT
25-03-07	B. Riley Cuts Price Target on Veru to $2 From $5, Keeps Buy Rating	MT
25-02-14	Oppenheimer Adjusts Price Target on Veru to $4 From $5, Keeps Outperform Rating	MT
25-01-27	Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study	CI
24-05-14	B. Riley Securities Starts Very With Buy Rating, $5 Price Target	MT
24-05-06	HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	MT
24-04-15	Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	MT
24-03-28	Raymond James Starts Very With Outperform Rating, $3 Price Target	MT
23-08-14	Oppenheimer Adjusts Veru Price Target to $7 From $9, Maintains Outperform Rating	MT
23-05-15	HC Wainwright Adjusts Price Target on Veru to $2 From $6, Maintains Buy Rating	MT
23-04-06	HC Wainwright Lowers Veru's Price Target to $6 From $14, Keeps Buy Rating	MT
23-03-15	Oppenheimer Adjusts Veru Price Target to $9 From $14, Maintains Outperform Rating	MT
23-02-14	Oppenheimer Adjusts Veru's Price Target to $14 From $20, Maintains Outperform Rating	MT
23-02-10	HC Wainwright Adjusts Price Target on Veru to $14 From $18, Maintains Buy Rating	MT
22-12-07	HC Wainwright Lowers Price Target on Veru to $18 From $21, Maintains Buy Rating	MT
22-11-10	HC Wainwright Cuts Price Target on Veru to $21 from $24, Keeps Buy Rating	MT
22-08-12	Cantor Fitzgerald Adjusts Veru's Price Target to $30 From $24, Reiterates Overweight Rating	MT
22-05-18	Brookline Capital Markets Adjusts Price Target for Veru to $31 From $29, Reiterates Buy Rating	MT
22-05-13	Jefferies Financial Raises Veru's Price Target to $55 From $33, Maintains Buy Rating	MT
22-04-12	HC Wainwright Adjusts Veru's Price Target to $24 from $21, Keeps Buy Rating	MT
22-04-12	Oppenheimer Adjusts Veru's Price Target to $36 From $25, Maintains Outperform Rating	MT
22-02-10	Oppenheimer Adjusts Veru Price Target to $25 From $26, Maintains Outperform Rating	MT
21-08-13	Veru : Oppenheimer Adjusts Veru PT to $26 From $24, Maintains Outperform Rating	MT
21-04-13	Veru : Jefferies Starts Veru at Buy with $19 Price Target	MT
21-02-11	Veru : Oppenheimer Adjusts Veru PT to $24 From $19, Maintains Outperform Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Financial estimates divergence	Objective/dr gap
VERU INC.	-	+891.9%
WUXI APPTEC CO., LTD.		+13.99%
ARGENX SE		+24.38%
LONZA GROUP AG		+19.43%
REVOLUTION MEDICINES, INC.		+29.48%
IQVIA HOLDINGS INC.		+11.87%
BEONE MEDICINES AG		+19.5%
CELLTRION, INC.		+46.79%
WUXI BIOLOGICS (CAYMAN) INC.		+0.6%
BIONTECH SE		+21.55%
Average		+107.95%
Weighted average by Cap.		+20.35%